We're currently experiencing extremely high call volumes. We're very sorry for any inconvenience this might cause.

If you need help with your account, please visit our Help Centre, or email us and we’ll get back to you as soon as we can. For more information and tips on managing your account online please visit www.hl.co.uk/coronavirus

We’re experiencing high call volumes, please check FAQs before calling.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Benchmark Holdings plc (BMK) Ordinary Shares

Sell:26.00p Buy:27.00p 0 Change: No change
FTSE AIM 100:1.09%
Market closed Prices as at close on 3 April 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Market closed Prices as at close on 3 April 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Market closed Prices as at close on 3 April 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Benchmark Holdings plc is engaged in the provision of aquaculture health, genetics and nutrition. The Company’s segments include genetics, advanced nutrition and health. The Company develops products that helps fish and shrimp to improve their sustainability and profitability by improving yield, quality, and by reducing mortality. The Company’s products include high genetic quality ova for salmon, shrimp and tilapia, and breeding, program, specialist feeds for early stage shrimp and fish; probiotics, Vaccines, biocides, and medicines.

Contact details

Benchmark House, 8 Smithy Wood Drive
S35 1QN
United Kingdom
+44 (0114) 2409939

Important dates

Future events
There are no future events available.
Past events
AGM 12 March 2020 12/03/20
General meeting 17 February 2020 17/02/20
Annual report 11 February 2020 11/02/20
Quarter 4 results 20 December 2019 20/12/19
Final results 20 December 2019 20/12/19
Trading Announcement 29 November 2019 29/11/19
Trading Announcement 12 August 2019 12/08/19
Interim results 25 June 2019 25/06/19
Trading Announcement 03 June 2019 03/06/19

General stock information

Market cap:
£176.88 million
Shares in issue:
667.47 million
Pharmaceuticals & Biotechnology
London Stock Exchange
Sterling pence

Key personnel

  • Peter George
    Executive Chairman of the Board
  • Septima Maguire
    Chief Financial Officer
  • Alex Raeber
    Chief Scientific Officer, Executive Director
  • Philippe Leger
    Interim Managing Director
  • Doerte Laue
    Marketing Director
  • Ivonne Cantu
    Director of Investor Relations
  • James Banfield
    Head of Knowledge Services
  • Athene Blakeman
    Head of Advanced Nutrition
  • Jan-Emil Johannessen
    Head of Benchmark Genetics
  • John Marshall
    Head of Animal Health

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.